Lale Öcal

Lale Öcal

Auto-generated profile, based on publicly available information

Lale Öcal

Division of Rheumatology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2016 in Microvascular Research
Verified
Journal Article
Closed access
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
SÇSuzan ÇINAR
Suzan ÇINAR
BABahar Artim-Esen
Bahar Artim-Esen
SKSevil Kamalı
Sevil Kamalı
ÖPÖzlem Pehlivan
Özlem Pehlivan
MIMurat Inanç
Murat Inanç

28 September 2022 in Rheumatology
Verified
Journal Article
Closed access
PDF file
RDRabia Deniz
Rabia Deniz
ZEZeliha Emrence
Zeliha Emrence
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
BEBahar Artım Esen
Bahar Artım Esen
MIMurat İnAnç
Murat İnAnç
AGAhmet Gül
Ahmet Gül
Objective: The skin pathergy test (SPT) is an important tool in the diagnosis of Behçet disease (BD), but its decreasing sensitivity over years has resulted in less frequent use in the clinical practice. This study aimed to improve the sensitivity of the SPT without compromising its specificity. Methods: BD patients, patients with other inflammatory diseases, recurrent aphthous stomatitis, and healthy controls comprised the study group. The SPT was conducted using 20G needle and 21G lancet pricks, or with additional application of 23-valent polysaccharide pneumococcal vaccine (PS-23), Alum, or ATP to the prick site. Development of erythema and induration at 24 h/48 h were evaluated by the same observer. Induration (≥2 mm) with erythema at 48 h was accepted as a positive reaction. Proinflammatory cytokine production following stimulation with lipopolysaccharide or PS-23 was investigated by whole-blood assay (WBA) in a subgroup. Results: Stimulation of the forearm skin by PS-23 and a 20G needle prick showed the highest sensitivity and specificity in BD (64.3% and 100%, respectively), especially in patients with active disease (80.3% and 100%, respectively), compared with a sensitivity of 4.8% in all and 6.1% in active patients using a single 20G prick. A positive result was associated with active disease and no use of immunosuppressives. In WBA, increased IL-1β and IL-1Ra production in response to PS-23 was observed in the group with active BD, while the cytokine response to lipopolysaccharide was similar in all groups. Conclusions: The SPT conducted using a 20G needle prick and PS-23 antigens was shown to be a promising tool for the diagnosis of BD owing to its improved sensitivity compared with the standard approach.

1 January 2021 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
NSNaci Senkal
Naci Senkal
EKEsen Kıyan
Esen Kıyan
ADAli Aslan Demir
Ali Aslan Demir
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
AGAhmet Gül
Ahmet Gül
BEBahar Artım Esen
Bahar Artım Esen
Systemic lupus erythematosus (SLE) is an autoimmune disease with a variety of organ/system involvement. Respiratory system involvement is common in these patients and usually manifests itself by disorders of the lung parenchyma, pleura, pulmonary vasculature or diaphragm. In this study, we sought to determine the frequency of interstitial lung disease (ILD) in patients with SLE and associated risk factors. Three hundred randomly chosen patients with SLE were included. Chest x-ray (CXR), lung spirometry and carbon monoxide diffusion test (DLCO) were performed. High-resolution thorax computed tomography (HRCT) was performed for a definite diagnosis of ILD. . Of 300 patients, 16% had ILD. At the start of the study, the prevalence obtained from the patients' records showed that 4% had ILD. The median age, mean duration of disease, and follow-up time were significantly higher and longer in patients with ILD compared to patients without (p < 0.05). Forced expiratory volume (FEV1), forced vital capacity (FVC), DLCO and total lung capacity (TLC) were significantly lower in patients with ILD (p < 0.001). Patients with ILD had a significantly higher frequency of arthritis, serositis, Raynaud's phenomenon, myositis, and anti-Scl70 positivity (p = 0.01, 0.001, 0.02, 0.004, and 0.001, respectively). A significantly higher number of patients had stopped using hydroxychloroquine (HCQ) in the ILD group (p = 0.04).

28 October 2020 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BIBurak Ince
Burak Ince
SASelay Artan
Selay Artan
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
BABahar Artim-Esen
Bahar Artim-Esen
AGAhmet Gul
Ahmet Gul
MIMurat Inanc
Murat Inanc

5 February 2021 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
BIBurak Ince
Burak Ince
SKSevil Kamali
Sevil Kamali
MBMurat Bektaş
Murat Bektaş
YOYeliz Ogret
Yeliz Ogret
FOFatma Savran Oguz
Fatma Savran Oguz
AGAhmet Gül
Ahmet Gül

12 December 2023 in TURKISH JOURNAL OF MEDICAL SCIENCES
Verified
Journal Article
Open access
PDF file
YYYasemin Yalcinkaya
Yasemin Yalcinkaya
BEBahar Artim Esen
Bahar Artim Esen
SAShirkhan Amikishiyev
Shirkhan Amikishiyev
NANumune Aliyeva
Numune Aliyeva
AGAhmet Gül
Ahmet Gül
MIMurat İnAnç
Murat İnAnç
Background/aim: B-cell depletion with rituximab (RTX) is widely used as a rescue therapy in patients with systemic sclerosis (SSc). The aim herein was to analyze the progress of disease-related outcomes after RTX therapy in severe SSc patients. Materials and methods: Included in this study were 27 SSc patients who were followed-up between 2012 and 2020 and received at least 1 cycle of RTX for active disease, despite receiving standard immunosuppressives (ISs). In addition to the European Scleroderma Study Group and European Scleroderma Trials and Research Group activity scores, Medsger's severity, and the recently developed Scleroderma Clinical Trials Consortium Damage Index values were evaluated initially and at 1 year after the first infusion. The progress of individual organ damage was also assessed at the end of the follow-up period (at least 6 months after the last infusion) using the data extracted from the medical records. Results: Disease activity and severity-improved and disease-related overall damage worsened after the first year of RTX therapy (p < 0.001, p = 0.008, and p = 0.005). Some of the disease-related organ damage had improved at the end of the follow-up period, indicating its reversibility. Overall damage scores -11 after the first year of RTX therapy were found to be associated with mortality (p = 0.035). Conclusion: RTX contributed to reducing the activity and severity in SSc patients with severe disease, nonetheless the efficacy related to the damage was limited. High damage scores in the first year were found to be associated with mortality. Spontaneous progress of manifestations requiring a longer period to improve and irregular consecutive RTX courses might lead to difficulties in differentiation between activity and damage.